Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Travere Therapeutics, Inc. chief medical officer Jula Inrig reported a bona fide gift of 468 shares of common stock to a donor-advised fund. The gift was authorized on June 16, 2026, and transferred on June 22, 2026, at a reported price of $0.00 per share. Following this charitable transfer, Inrig directly holds 112,770 shares of Travere Therapeutics common stock, indicating this was a relatively small, non-market transaction within her overall position.
Positive
- None.
Negative
- None.
Insider Trade Summary
468 shares gifted
Mixed
1 txn
Insider
Inrig Jula
Role
CHIEF MEDICAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 468 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 112,770 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Shares gifted: 468 shares
Reported gift price: $0.00 per share
Shares held after transaction: 112,770 shares
+1 more
4 metrics
Shares gifted
468 shares
Bona fide gift of Travere common stock
Reported gift price
$0.00 per share
Gift of 468 shares to donor-advised fund
Shares held after transaction
112,770 shares
Direct holdings following June 22, 2026 gift
Gift transaction count
1 transaction
Form 4 transactionSummary giftCount
Key Terms
bona fide gift, donor-advised fund, Common Stock
3 terms
bona fide gift financial
"This transaction represents a bona fide gift of 468 shares of common stock"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
donor-advised fund financial
"gift of 468 shares of common stock to a donor-advised fund"
A donor-advised fund is a charitable giving account that lets an individual or family deposit cash, stock, or other assets now, get an immediate tax benefit, and then recommend grants to charities over time. Think of it like a private charitable bucket you control without running a charity yourself; investors care because it’s a tax-efficient way to give appreciated securities, can change when and how donated shares enter the market, and affects personal and corporate tax planning.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did Travere Therapeutics (TVTX) report for Jula Inrig?
Travere’s chief medical officer Jula Inrig reported a bona fide gift of 468 common shares. The shares were donated to a donor-advised fund, reflecting a charitable transfer rather than a market trade involving a purchase or sale of Travere stock.
Was the Travere Therapeutics (TVTX) Jula Inrig transaction a stock sale?
No, the transaction was not a sale. Jula Inrig made a bona fide gift of 468 Travere common shares to a donor-advised fund, reported at a price of $0.00 per share, meaning no cash proceeds were received from this transfer.
When did Jula Inrig’s Travere Therapeutics (TVTX) stock gift occur?
Jula Inrig authorized the gift on June 16, 2026, and the transfer of 468 Travere Therapeutics common shares to a donor-advised fund occurred on June 22, 2026, as reflected in the Form 4 insider transaction disclosure.
What does a bona fide gift mean in the Travere Therapeutics (TVTX) Form 4?
A bona fide gift in this context means shares were transferred without payment as a genuine charitable contribution. For Travere Therapeutics, Jula Inrig donated 468 common shares to a donor-advised fund, reflecting a non-market disposition rather than an investment-driven trade.